Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly improve patient outcomes in mismatch repair-deficient (dMMR) CRC. Now, they are part of the standard of care for this subset of CRC. Because of this, there has been a growing interest in the efficacy and timing of immunotherapy for other subsets of CRC, including locally advanced, metastatic, and microsatellite stable (MSS). In this review, we aim to examine the three main classes of immunotherapy for CRC—immune checkpoint inhibitors (ICIs), adoptive cell transfer therapy (ACT), and tumor vaccines—and discuss the most recent advances and future directions for each.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This subset of CRC exhibits high immunogenicity due to increased mutational burden, inducing high immune cell infiltration, particularly from tumor-infiltrating lymphocytes [37,38].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“CTLA-4 is expressed on some T cells, such as regulatory T cells [5], which play a role in maintaining self-tolerance [6], as well as activated CD4+ T cells [7], which play a role in generating an antitumor response from the immune system [8].”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“In the landmark trial, it was demonstrated that one in every four to five patients with melanoma, renal cell carcinoma, or non-small-cell lung cancer had significant responses to anti-PD-1 treatment [11].”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 2×
“Additionally, there are studies indicating that the microbiome [53,54] and diet [55] can alter tumor responses to ICIs.”
BackgroundBoland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 2×
“Additionally, there are studies indicating that the microbiome [53,54] and diet [55] can alter tumor responses to ICIs.”
BackgroundTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 1×
“Additionally, pMMR CRC has a lower mutational burden and fewer antigens that can be detected by cytotoxic T cells, which are associated with a poor response to ICIs [43,46].”
BackgroundPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 3×
“Almost 50% of patients were progression-free at 24 months and were able to discontinue treatment [22].”
BackgroundInfluentialGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · cited 1×
“In the KEYNOTE-158 trial, there were clinically meaningful responses to Pembrolizumab across patients with high TMB, but interestingly, MSI-H status did not account entirely for the clinical benefit seen [29].”
BackgroundiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201445 · Cited by 1,625 · cited 2×
“Adverse effects were lower than grade 3 across all patients [42].”
BackgroundPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 9×
“This is nicely demonstrated in the NICHE trial, which evaluated the neoadjuvant response of early-stage colon cancer to the combination of Nivolumab and Ipilimumab [20].”
BackgroundInfluentialChalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417 · cited 11×
“This is nicely demonstrated in the NICHE trial, which evaluated the neoadjuvant response of early-stage colon cancer to the combination of Nivolumab and Ipilimumab [20].”
BackgroundMethodInfluentialImmune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · cited 1×
“The resulting signal cascade inhibits T-cell proliferation, weakens T-cell function [10], and decreases cytokine production [9], allowing the tumor cell to escape attack by the body’s immune system.”
BackgroundHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · cited 9×
“This is nicely demonstrated in the NICHE trial, which evaluated the neoadjuvant response of early-stage colon cancer to the combination of Nivolumab and Ipilimumab [20].”
BackgroundInfluentialA conserved dendritic-cell regulatory program limits antitumour immunity
Maier, B., Leader, A. M., Chen, S. T., Tung, N., Chang, C., LeBerichel, J., Chudnovskiy, A., Maskey, S., Walker, L., Finnigan, J. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2134-y · Cited by 941
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890 · cited 1×
“3% in MSS CRC patients [49], suggesting that further investigations into ICI combination therapy are still warranted, despite the negative results from the IMblaze370 trial.”
ResultTumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0522 · Cited by 859 · cited 1×
“One such biomarker is the tumor mutational burden (TMB), which quantifies the total number of somatic mutations per megabase of the tumor genome that has been interrogated [28].”
BackgroundRevisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813 · cited 1×
“CTLA-4 is expressed on some T cells, such as regulatory T cells [5], which play a role in maintaining self-tolerance [6], as well as activated CD4+ T cells [7], which play a role in generating an antitumor response from the immune system [8].”
BackgroundBrown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764 · cited 1×
“Certain strategies have been proposed to counteract these barriers, such as direct administration to the tumor instead of systemic administration [88], as well as co-administration with various substances, such as collagenases that could help break down physical barriers [89].”
BackgroundLenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01015 · Cited by 728 · cited 2×
“Of this cohort, 13% achieved a complete pathologic response with a response rate of 69%, with a median follow up of nearly 2 years [41].”
BackgroundThe PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Dammeijer, F., van Gulijk, M., Mulder, E. E., Lukkes, M., Klaase, L., van den Bosch, T., van Nimwegen, M., Lau, S. P., Latupeirissa, K., Schetters, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.001 · Cited by 695 · cited 1×
“It is understood that drugs targeting the PD-1/PD-L1 pathway exert their influence by re-invigorating exhausted T cells within the tumor microenvironment [60], but recent studies indicate that there may be many more interactions at play here than first initially realized.”
BackgroundEng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577 · cited 2×
“The IMblaze370 trial, for example, was a multi-center and open-label phase 3 randomized controlled trial that evaluated Atezolizumab, an anti-PD-L1 monoclonal antibody, alone and in combination with Cobimetinib, a MEK inhibitor [47].”
MethodResultXu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 558 · cited 1×
“Toxicities more commonly associated with Pembrolizumab include arthralgias, hepatic toxicity, and pneumonitis, while Nivolumab affects the endocrine system, and Ipilimumab affects the skin, gastrointestinal tract, and kidneys [32].”
BackgroundDurable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545 · cited 1×
“This patient had a complete response [12].”
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., & Engleman, E. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141226398 · Cited by 541
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Oh, S. A., Wu, D.-C., Cheung, J., Navarro, A., Xiong, H., Cubas, R., Totpal, K., Chiu, H., Wu, Y., Comps-Agrar, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0075-x · Cited by 459 · cited 1×
“DCs in the tumor-draining lymph nodes have been shown to upregulate PD-L1 expression upon ingestion of apoptotic tumor cells, which similarly results in decreased T-cell induction [65], but when PD-L1 is deleted in DCs, tumor growth is restricted as a result, and antitumor CD8+ T-cell responses are enhanced [66].”
BackgroundPhase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., Zhang, R., Xiong, Z., Wei, Z., Shen, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.010 · Cited by 451 · cited 1×
“CEA is usually not detected in most normal adult tissues, which may contribute to the overall tolerance to treatment seen in studies evaluating the safety profile of CEA CAR T-cell therapy [84].”
BackgroundDendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394 · cited 2×
“1 sequestration, allowing DCs in the tumor microenvironment to exert their T-cell priming effects [64].”
BackgroundClinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning
Echle, A., Grabsch, H. I., Quirke, P., van den Brandt, P. A., West, N. P., Hutchins, G. G. A., Heij, L. R., Tan, X., Richman, S. D., Krause, J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.021 · Cited by 376 · cited 1×
“There are novel assessments of microsatellite status, such as the deep learning assay, which classifies tumors based on morphological patterns seen on pathology slides that are also under investigation [27].”
BackgroundHodi, F. S., Ballinger, M., Lyons, B., Soria, J.-C., Nishino, M., Tabernero, J., Powles, T., Smith, D., Hoos, A., McKenna, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1644 · Cited by 366 · cited 1×
“Pseudoprogression can be identified using tumor response scores, such as immune Response Evaluation Criteria in Solid Tumors (iRECIST) [39] and immune-modified Response Evaluation Criteria in Solid Tumors (imRECIST) [40], along with biopsies of new or enlarging lesions and radiographic follow up [37].”
MethodProgrammed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Hartley, G. P., Chow, L., Ammons, D. T., Wheat, W. H., & Dow, S. W. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0537 · Cited by 351 · cited 1×
“Treatment of macrophages with anti-PD-L1 antibodies in both mouse and human models has demonstrated a resulting increase in spontaneous macrophage activation, proliferation, and survival, along with increased tumor infiltration of these macrophages [63], consistent with this theory.”
ResultImplementing TMB measurement in clinical practice: considerations on assay requirements
Büttner, R., Longshore, J. W., López-Ríos, F., Merkelbach-Bruse, S., Normanno, N., Rouleau, E., & Penault-Llorca, F. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000442 · Cited by 345 · cited 1×
“Therefore, it is suggested that TMB assay testing occurs in tandem with germline mutation testing [30].”
BackgroundDong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 302 · cited 2×
“demonstrate response to anti-PD-L1 therapy [61,62], and it has been suggested that the presence of PD-L1 on myeloid cells in the tumor microenvironment plays an essential role.”
BackgroundTu, X., Qin, B., Zhang, Y., Zhang, C., Kahila, M., Nowsheen, S., Yin, P., Yuan, J., Pei, H., Li, H., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.04.005 · Cited by 263 · cited 2×
“developed an anti-PD-L1 antibody, H1A, that targets intracellular PD-L1, allowing for destabilization of the PD-L1 and RNA complex, which could allow for improved sensitization to other systemic therapies, such as radiation and chemotherapy [69].”
BackgroundFessas, P., Lee, H., Ikemizu, S., & Janowitz, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.002 · Cited by 255 · cited 12×
“This is nicely demonstrated in the NICHE trial, which evaluated the neoadjuvant response of early-stage colon cancer to the combination of Nivolumab and Ipilimumab [20].”
BackgroundInfluentialCAR T‐cell therapy of solid tumors
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2016.128 · Cited by 220 · cited 1×
“These include physical barriers, such as tumor endothelium [83] and stroma [81], metabolic barriers, such as increased oxidative stress from increased lactic acid production within tumors [86], and immunologic barriers, such as the presence of certain cytokines within the tumor microenvironment that inhibit the prolif…”
BackgroundAndre, T., Amonkar, M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D., Garcia-Carbonero, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00064-4 · Cited by 209 · cited 1×
“Further investigation into the quality of life of patients treated with Pembrolizumab also demonstrated significant improvements compared to chemotherapy [23].”
BackgroundJia, W., Gao, Q., Han, A., Zhu, H., & Yu, J. (2019) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2019.0144 · Cited by 192 · cited 2×
“Pseudoprogression can be identified using tumor response scores, such as immune Response Evaluation Criteria in Solid Tumors (iRECIST) [39] and immune-modified Response Evaluation Criteria in Solid Tumors (imRECIST) [40], along with biopsies of new or enlarging lesions and radiographic follow up [37].”
BackgroundMethodChalabi, M., Verschoor, Y. L., van den Berg, J., Sikorska, K., Beets, G., Lent, A. V., Grootscholten, M. C., Aalbers, A., Buller, N., Marsman, H., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.016 · Cited by 191 · cited 1×
“To this end, the NICHE-2 trial was conducted [35].”
MethodExosomal PD-L1: Roles in Tumor Progression and Immunotherapy
Morrissey, S. M., & Yan, J. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.03.002 · Cited by 172 · cited 2×
“PD-L1 may also be secreted by tumors in exosomes, which contributes to both local and systemic resistance to the body’s natural antitumor response by stimulating macrophages and monocytes to display a protumorigenic phenotype [68].”
BackgroundResultSchmeel, L. C., Schmeel, F. C., Coch, C., & Schmidt‐Wolf, I. G. H. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1864-3 · Cited by 154 · cited 1×
“Nonetheless, there are multiple studies showing that the side-effect profile of CIK therapy is tolerable [77,78], consisting most frequently of mild fevers, headaches, chills, and fatigue [79].”
BackgroundOpzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 152
Gujar, S. A., Pol, J. G., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442169 · Cited by 149 · cited 1×
“Additionally, infection of the tumor by these oncolytic viruses has been shown to change various cold tumors, including brain, colorectal, and breast tumors, into hot tumors, which has the potential to greatly increase the efficacy of concurrent ICI administration [97,98].”
Backgroundde Salins, A. G. D., Tachon, G., Cohen, R., Karayan, L., Junca, A., Frouin, É., Godet, J., Evrard, C., Randrian, V., Duval, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100120 · Cited by 138 · cited 3×
“Interestingly, there have been past reports of discordance between immunohistochemistry testing and molecular assays, ranging from 1 to 10%, but a recent study demonstrated high concordance [26], suggesting that the newer tests are quite reliable and valid for clinical use.”
BackgroundInfluentialCAR T-Cell Therapy: Adverse Events and Management
Adkins, S. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.4.11 · Cited by 136 · cited 1×
“Despite the possible benefits that CAR therapy can provide, there are a number of unique adverse effects that have also been documented, including cytokine release syndrome, neurologic toxicity and encephalopathy, and various types of cytopenia, leading to infection [82].”
BackgroundHecht, M., Büttner-Herold, M. J., Erlenbach‐Wünsch, K., Haderlein, M., Croner, R. S., Grützmann, R., Hartmann, A., Fietkau, R., & Distel, L. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.015 · Cited by 134 · cited 1×
“Chemotherapy and radiation have been proposed to induce tumor sensitization to ICIs by various mechanisms, including converting a cold or excluded tumor to a hot one by recruiting T cells to the tumor microenvironment [50] and inducing PD-L1 expression in the cancer cells as a possible target for immunotherapy [51,52].”
BackgroundActivated T cells and cytokine-induced CD3 + CD56 + killer cells
Schmidt‐Wolf, G., Negrin, R. S., & Schmidt‐Wolf, I. G. H. (1997) · Annals of Hematology · doi:10.1007/s002770050257 · Cited by 134 · cited 1×
“These cells are then returned to the patient where they exert their cytotoxic functions against cancer cells [75].”
BackgroundPD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Kleinovink, J. W., Marijt, K. A., Schoonderwoerd, M. J. A., van Hall, T., Ossendorp, F., & Fransen, M. F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1294299 · Cited by 133 · cited 1×
“demonstrate response to anti-PD-L1 therapy [61,62], and it has been suggested that the presence of PD-L1 on myeloid cells in the tumor microenvironment plays an essential role.”
BackgroundNarayanan, S., Kawaguchi, T., Peng, X., Qi, Q., Liu, S., Yan, L., & Takabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-49878-4 · Cited by 132 · cited 1×
“Such neoantigens then attract tumor-infiltrating lymphocytes (TILs), making the tumor “hot” and improving the response to immunotherapy [18,19].”
BackgroundSelf-citationLiu, Y., Zhou, Z., Hou, J.-T., Xiong, W., Kim, H., Chen, J., Zheng, C., Jiang, X., Yoon, J., & Shen, J. (2022) · Advanced Materials · doi:10.1002/adma.202206121 · Cited by 129 · cited 1×
“There have been several studies demonstrating that overexpression of PD-L1 in the tumor microenvironment can also hamper the effect of photodynamic immunotherapy [71,72].”
ResultChan, D. V., Gibson, H. M., Aufiero, B. M., Wilson, A. J., Hafner, M. S., Mi, Q.-S., & Wong, H. K. (2014) · Genes & Immunity · doi:10.1038/gene.2013.57 · Cited by 128 · cited 1×
“CTLA-4 is expressed on some T cells, such as regulatory T cells [5], which play a role in maintaining self-tolerance [6], as well as activated CD4+ T cells [7], which play a role in generating an antitumor response from the immune system [8].”
BackgroundMetabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy
Zhou, Z., Liu, Y., Song, W., Jiang, X., Deng, Z., Xiong, W., & Shen, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.004 · Cited by 118 · cited 1×
“There have been several studies demonstrating that overexpression of PD-L1 in the tumor microenvironment can also hamper the effect of photodynamic immunotherapy [71,72].”
Resultvan den Berg, I., van den Braak, R. R. J. C., van Vugt, J. L. A., IJzermans, J. N. M., & Buettner, S. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02207-4 · Cited by 107 · cited 2×
“For stage I cancers, upfront resection has a high cure rate of greater than 90% without the need for additional adjuvant or neoadjuvant therapy [31].”
BackgroundGao, D., Li, C., Xie, X., Zhao, P., Wei, X., Sun, W., Liu, H.-C., Alexandrou, A. T., Jones, J., Zhao, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093886 · Cited by 106 · cited 1×
“Analysis revealed a statistically significant decrease in the risk of tumor progression as well as a statistically significant increase in overall survival [90].”
BackgroundOshi, M., Asaoka, M., Tokumaru, Y., Angarita, F. A., Yan, L., Matsuyama, R., Zsiros, E., Ishikawa, T., Endo, I., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12103038 · Cited by 105 · cited 1×
“CTLA-4 is expressed on some T cells, such as regulatory T cells [5], which play a role in maintaining self-tolerance [6], as well as activated CD4+ T cells [7], which play a role in generating an antitumor response from the immune system [8].”
BackgroundSelf-citationOncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
Ge, Y., Wang, H., Ren, J., Liu, W., Chen, L., Chen, H., Ye, J., Dai, E., Ma, C., Ju, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000710 · Cited by 91 · cited 1×
“Additionally, infection of the tumor by these oncolytic viruses has been shown to change various cold tumors, including brain, colorectal, and breast tumors, into hot tumors, which has the potential to greatly increase the efficacy of concurrent ICI administration [97,98].”
BackgroundYarchoan, M., Huang, C., Zhu, Q., Ferguson, A. K., Durham, J. N., Anders, R. A., Thompson, E. D., Rozich, N. S., Thomas, D. L., Nauroth, J. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2763 · Cited by 88
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González-Vallinas, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111781 · Cited by 86 · cited 2×
“This type of therapy has seen the most success against hematological malignancies in the United States [83].”
BackgroundHypermutation and microsatellite instability in gastrointestinal cancers
Yuza, K., Nagahashi, M., Watanabe, S., Takabe, K., & Wakai, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22783 · Cited by 86 · cited 1×
“Such neoantigens then attract tumor-infiltrating lymphocytes (TILs), making the tumor “hot” and improving the response to immunotherapy [18,19].”
BackgroundSelf-citationThe current clinical landscape of personalized cancer vaccines
Fritah, H., Rovelli, R., Chiang, C. L.-L., & Kandalaft, L. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102383 · Cited by 86 · cited 1×
“Unfortunately, the vaccines have not been particularly efficacious, and there has not been significant success in utilizing them in patient care [91].”
BackgroundSegal, N. H., Cercek, A., Ku, G., Wu, A. J., Rimner, A., Khalil, D. N., Reidy-Lagunes, D., Cuaron, J., Yang, T. J., Weiser, M. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2474 · Cited by 84 · cited 1×
“Interestingly, some of these studies have shown that certain patients demonstrate an abscopal response, defined as a response in non-irradiated distant tumors after receiving the combination therapy of radiation to a targeted tumor and ICIs [57,58].”
BackgroundIs There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli, F., & Fumet, J.-D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01816 · Cited by 84 · cited 2×
“This is attributed largely to two mechanisms of resistance: immunoexclusion and lack of antigens [43].”
BackgroundThe Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier
Pai, S. I., Cesano, A., & Marincola, F. M. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_6 · Cited by 81 · cited 1×
“Tumors are considered “hot” if there is a high density of T cells in the core, “excluded” if there is high density only at the outer invasive margin and not the core, and “cold” if all areas of the tumor have low T-cell density [44].”
BackgroundItoh, T., Ueda, Y., Kawashima, I., Nukaya, I., Fujiwara, H., Fuji, N., Yamashita, T., Yoshimura, T., Okugawa, K., Iwasaki, T., et al. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-001-0257-z · Cited by 80
Current status and limitations of immunotherapy for breast cancer
Tokumaru, Y., Joyce, D., & Takabe, K. (2019) · Surgery · doi:10.1016/j.surg.2019.09.018 · Cited by 80 · cited 1×
“An immune checkpoint inhibitor (ICI) is a class of drug that prevents malignant cells from downregulating host cell immune responses against the tumor [2].”
BackgroundSelf-citationSegal, N. H., Kemeny, N. E., Cercek, A., Reidy‐Lagunes, D. L., Raasch, P. J., Warren, P., Hrabovsky, A. E., Campbell, N. M., Shia, J., Goodman, K. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3539 · Cited by 79 · cited 1×
“Interestingly, some of these studies have shown that certain patients demonstrate an abscopal response, defined as a response in non-irradiated distant tumors after receiving the combination therapy of radiation to a targeted tumor and ICIs [57,58].”
BackgroundNagasaka, M., Potugari, B., Nguyen, A., Sukari, A., Azmi, A. S., & Ou, S.-H. I. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102309 · Cited by 76 · cited 1×
“After administration, APCs then translate the mRNA to a neoantigen peptide and present it on MHC molecules, stimulating the cytotoxic T-lymphocyte and memory T cell immune response against tumor cells that express the same neoantigen [92].”
BackgroundAndré, T., Cohen, R., & Salem, M. E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349557 · Cited by 74 · cited 1×
“This has been attributed to three possible causes: primary resistance, misdiagnosis of dMMR status, and pseudoprogression [36], which is defined as progression following initiation of therapy in the form of increased tumor size or presence of new lesions, followed by an overall decrease in tumor burden [37].”
BackgroundZhou, Z., Chen, J., Liu, Y., Zheng, C., Luo, W., Chen, L., Zhou, S., Li, Z., & Shen, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.023 · Cited by 68 · cited 1×
“These nanoparticles have also been shown to decrease the growth of solid tumors [73] and disrupt the PD-1/PD-L1 cascade, resulting in an improved antitumor T-cell effect.”
BackgroundStein, A., Simnica, D., Schultheiß, C., Scholz, R., Tintelnot, J., Gökkurt, E., von Wenserski, L., Willscher, E., Paschold, L., Sauer, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002844 · Cited by 67 · cited 1×
“The authors of the AVETUX trial also identified a certain subpopulation of patients, specifically those with the FcγR3a V-allele [56], that showed a trend towards clinical benefit in otherwise unsuccessful drug combinations, concluding that further research into these subpopulations may yield interesting results.”
ResultAndre, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Alcaide, J., Gibbs, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3500 · Cited by 67
An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome
Therkildsen, C., Jensen, L. H., Rasmussen, M., & Bernstein, I. (2021) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s278054 · Cited by 66 · cited 2×
“Lynch syndrome predisposes patients to a variety of malignancies, frequently of the colon and endometrium, but also of the ovaries, small bowel, and urinary tract [25].”
BackgroundLiu, J., Gao, T., Tan, Z., Li, S., Xu, J. H., Bai, C., Xue, R., Xie, L., Zhang, L., Fan, Z., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0871 · Cited by 57
Chen, T.-W., Huang, K. C., Chiang, S., Chen, W. T., Ke, T., & Chao, K. S. C. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02874-7 · Cited by 56 · cited 1×
“Chemotherapy and radiation have been proposed to induce tumor sensitization to ICIs by various mechanisms, including converting a cold or excluded tumor to a hot one by recruiting T cells to the tumor microenvironment [50] and inducing PD-L1 expression in the cancer cells as a possible target for immunotherapy [51,52].”
BackgroundHan, S., Zong, S., Shi, Q. W., Li, H., Liu, S., Yang, W., Li, W., & Hou, F. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.025 · Cited by 50 · cited 1×
“Its presence has been associated with cell invasion and migration [85].”
BackgroundAdvances of immune checkpoints in colorectal cancer treatment
Jiao, Q., Ren, Y., Gabrie, A. N. A., Wang, Q., Wang, Y., Du, L., Liu, X., Wang, C., & Wang, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109745 · Cited by 50 · cited 1×
“The resulting signal cascade inhibits T-cell proliferation, weakens T-cell function [10], and decreases cytokine production [9], allowing the tumor cell to escape attack by the body’s immune system.”
BackgroundPecci, F., Cantini, L., Bittoni, A., Lenci, E., Lupi, A., Crocetti, S., Giglio, E., Giampieri, R., & Berardi, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00870-z · Cited by 49 · cited 1×
“Examination of pMMR CRC tumors show that they fall under the “excluded” category, and this lack of T cells at the tumor core may explain, in part, why ICI monotherapy, which requires direct contact with T cells, has been unsuccessful [45].”
BackgroundDendritic cell vaccine therapy for colorectal cancer
Wooster, A. L., Girgis, L. H., Brazeale, H., Anderson, T. S., Wood, L. M., & Lowe, D. B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105374 · Cited by 48 · cited 2×
“Dendritic cell (DC) vaccines are most frequently created by pulsing DCs with autologous tumor lysates, thus, exposing the DCs to the tumor antigens unique to the patient’s tumor [93].”
BackgroundNanoparticle-Mediated Delivery Systems in Photodynamic Therapy of Colorectal Cancer
Simelane, N. W. N., & Abrahamse, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212405 · Cited by 47 · cited 2×
“Lastly, photodynamic immunotherapy is a newer immunotherapy modality that functions by applying light irradiation to photosensitizers, inducing reactive oxygen species that are then taken up by tumor cells, leading to apoptosis [70].”
BackgroundMethodNK cells limit therapeutic vaccine–induced CD8 + T cell immunity in a PD-L1–dependent manner
Diniz, M. O., Schurich, A., Chinnakannan, S. K., Duriez, M., Stegmann, K. A., Davies, J. E., Kucykowicz, S., Suveizdytė, K., Amin, O. E., Alcock, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi4670 · Cited by 47
Zhu, H., Yang, X., Li, J., Ren, Y., Zhang, T., Zhang, C., Zhang, J., Li, J., & Pang, Y. (2014) · BioMed Research International · doi:10.1155/2014/603871 · Cited by 45 · cited 2×
“Nonetheless, there are multiple studies showing that the side-effect profile of CIK therapy is tolerable [77,78], consisting most frequently of mild fevers, headaches, chills, and fatigue [79].”
BackgroundNeoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Zheng, Y., Fu, Y., Wang, P., & Ding, Z. (2022) · Disease Markers · doi:10.1155/2022/8270305 · Cited by 43 · cited 1×
“These neoantigens are particularly useful in immunotherapy when they are presented on major histocompatibility complex (MHC) molecules and when their expression induces an immune response by CD4+ or CD8+ T cells [17].”
BackgroundLiu, X., Jiang, S., Wang, H., Wu, X., Yan, W., Chen, Y., Xu, Y., Wang, C., Yao, W., Wang, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1785 · Cited by 38 · cited 1×
“For example, TQB2450 is a novel humanized anti-PD-L1 monoclonal antibody that has shown promising results in the treatment of multiple tumors [59] and is currently being studied in combination with immunotherapy, chemotherapy, and other novel agents (NCT05645315, NCT04611711, NCT05139082, NCT03897283).”
BackgroundSumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36 · cited 3×
“Carcinoembryonic antigen (CEA) has been evaluated as a target due to its overexpression in at least half of all CRC [74].”
BackgroundInfluentialGorzo, A., Galoș, D., Volovăț, S. R., Lungulescu, C. V., Burz, C. C., & Sur, D. G. (2022) · Life · doi:10.3390/life12020229 · Cited by 34 · cited 2×
“These cells have often undergone gene modification to make them more effective at recognizing a certain neoantigen and eliminating the cell expressing it [16].”
BackgroundEstimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Kunst, N., Alarid‐Escudero, F., Aas, E., Coupé, V. M. H., Schrag, D., & Kuntz, K. M. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0490 · Cited by 34 · cited 1×
“For stage II and III cancers, however, the 10-year cumulative risk of recurrence is significantly higher [31,34].”
BackgroundGarcía‐Olmo, D., Villarejo‐Campos, P., Barambio, J., Gómez‐Heras, S. G., Vega-Clemente, L., López, S. O., Guadalajara, H., & García‐Arranz, M. (2021) · Scientific Reports · doi:10.1038/s41598-020-79721-0 · Cited by 29 · cited 1×
“Certain strategies have been proposed to counteract these barriers, such as direct administration to the tumor instead of systemic administration [88], as well as co-administration with various substances, such as collagenases that could help break down physical barriers [89].”
BackgroundLow-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer
Lee, D., Kim, D., Lee, H. S., Ihn, M. H., Oh, H., Min, B. S., Kim, W. R., Huh, J. W., Yun, J.-A., Lee, K. Y., et al. (2015) · Medicine · doi:10.1097/md.0000000000002260 · Cited by 27 · cited 1×
“Approximately 15% of CRC is classified as MSI, which can be further divided into high microsatellite instability (MSI-H) and low microsatellite instability (MSI-L), where instability is demonstrated at greater than or less than 30–40% of loci, respectively [14].”
BackgroundNiu, J.-X., Ren, Y., Zhang, T., Yang, X., Zhu, W., Zhu, H., Li, J., Li, J., & Pang, Y. (2014) · BioMed Research International · doi:10.1155/2014/214727 · Cited by 26 · cited 1×
“Nonetheless, there are multiple studies showing that the side-effect profile of CIK therapy is tolerable [77,78], consisting most frequently of mild fevers, headaches, chills, and fatigue [79].”
BackgroundHunyadi, J., András, C., Szabó, I., Szántó, J., Szluha, K., Sipka, S., Kovacs, P. L., Kiss, A., Szegedi, G., Altorjay, I., et al. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9704-3 · Cited by 23
Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
Fayyaz, F., Yazdanpanah, N., & Rezaei, N. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00836-0 · Cited by 22 · cited 1×
“One of the obstacles to this is the large quantity of cell transfusions that need to occur due to poor cell-migration ability [76].”
BackgroundQian, S., Villarejo‐Campos, P., Castellano, I. G., Hernández‐Villafranca, S., García‐Olmo, D., González-Soares, S., Guadalajara, H., Jiménez-Galanes, S., & Qian, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841425 · Cited by 21
Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y. (2022) · Life · doi:10.3390/life12030409 · Cited by 18 · cited 2×
“Additionally, there are studies indicating that the microbiome [53,54] and diet [55] can alter tumor responses to ICIs.”
BackgroundDu, C., Liu, Z., Ding, Z., Guo, F., Ma, D., & Xie, X. (2013) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-013-1214-y · Cited by 9 · cited 1×
“Patients who received CIK therapy also report an improved quality of life [78,80].”
BackgroundFu, Y., Ye, Y., Liu, X., Zhu, G., Xu, Y., Sun, J., Wu, H., Feng, F., Wen, Z., Jiang, S., et al. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2762 · Cited by 9 · cited 1×
“The remaining 85% of CRC is classified as microsatellite stable (MSS), with proficiency in mismatch repair (pMMR) [15].”
Background
Cited by
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
“The purpose of these vaccines is to create an immune response against tumor antigens, and they are usually administered together with an adjuvant or combined with other immunotherapy methods to increase efficiency [160].”
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“The most common ICIs are PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and CTLA-4 inhibitors (e.g., ipilimumab), which activate T cells to induce an antitumor response from the immune system (Figure 2) [38].”
Magnetic Particle Imaging: From Tracer Design to Biomedical Applications in Vasculature Abnormality
Xie, X., Zhai, J., Zhou, X., Guo, Z., Lo, P., Zhu, G., Chan, K. W. Y., & Yang, M. (2023) · Advanced Materials · doi:10.1002/adma.202306450 · Cited by 62
Kaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 53
Plant Foods and Their Bioactives as Dietary Enhancers for Colon Cancer Treatment with 5-Fluorouracil
Yang, Z., Céspedes, C. L., Yang, Z., Bakar, M. Z. A., Chan, K. W., & Deng, X. (2025) · Food Reviews International · doi:10.1080/87559129.2024.2446366 · Cited by 39
“[5,48,49] Chemotherapy is essential in treating CC across all stages, particularly in advanced stages, as it targets and destroys cancer cells that may not be removed by surgery.”
Metadata
- Authors
- Yu, I., Dakwar, A., & Takabe, K.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- Corresponding author
- Takabe, Kazuaki
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-01-08
- Volume
- 12
- Issue
- 2
- Pages
- 258
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9856401
- OpenAlex
- W4313825882
- Cited by
- 40
- References
- 99
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 8 · 2023: 9
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health, USA (P30 CA016056/CA/NCI)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, immunotherapy, immune checkpoint inhibitors, mismatch repair deficiency, neoadjuvant therapy, adjuvant therapy, primary treatment, metastatic colorectal cancer, locally advanced colorectal cancer, microsatellite stable colorectal cancer, adoptive cell transfer, cancer vaccines
- MeSH terms
- Immune Checkpoint Inhibitors, Adjuvants, Immunologic, Adjuvants, Pharmaceutic, Brain Neoplasms, Humans, Immunotherapy, Neoplastic Syndromes, Hereditary, Colorectal Neoplasms, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.